Syncromune

Executive Summary

Syncromune is a private biopharmaceutical company developing SYNC-T®, a novel platform immunotherapy designed to synchronize the three key components required to educate the immune system to recognize and attack cancer: antigen presentation, T-cell activation, and immune checkpoint modulation. The therapy is administered intratumorally and aims to induce systemic anti-tumor immunity. Syncromune is currently enrolling patients in its phase 2 LEGION-100 trial evaluating SYNC-T in metastatic castration-resistant prostate cancer (mCRPC), a challenging indication with high unmet need. The trial is ongoing across multiple US sites, and preliminary data are expected in the coming months. The platform's potential extends beyond prostate cancer to other solid tumors, positioning Syncromune as a promising player in the immuno-oncology space, though the company remains early-stage with no approved products or disclosed financials.

Upcoming Catalysts (preview)

• Q4 2026Interim data from LEGION-100 phase 2 trial50% success
• Q3 2026Completion of enrollment for LEGION-100 trial80% success
• TBDPresentation of preclinical data for new indications60% success